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Objective: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment
under real-life heterogeneity in patients, settings, and physicians in an open-label, multi-
center, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in
Belgium.
Methods: Effectiveness outcomes included improvement in 2005 global initiative for asthma
(GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE),RSIST study, we observed better physician-rated effectiveness, greater improvements in quality of
evere exacerbations, and greater reductions in healthcare utilization than previously reported in
in the treatment of severe persistent allergic asthma. Thus, under ‘‘real-life’’ heterogeneity in
an practices, omalizumab is effective as add-on therapy in the treatment of patients with persistent
0 Frays Ridge Road, Earlysville, VA 22936, USA. Tel.: þ1 267 978 0713; fax: þ1 978 945 8374.
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1634 G. Brusselle et al.quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life ques-
tionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included
both intent-to-treat and per-protocol populations.
Results: The sample (nZ 158) had a mean age of 48.17 17.18 years, and a slight majority
were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-
acting b2-agonists, all patients experienced frequent symptoms and had exacerbations in
the past year. At 16 weeks, >82% had good/excellent GETE (P values <0.001), >82% had an
improvement in total AQLQ scores of 0.5 points (P< 0.001), and >91% were severe exacer-
bation-free (P< 0.001). At 52 weeks, >72% had a good/excellent GETE rating (P< 0.001),
>84% had improvements in total AQLQ score of 0.5 points (P< 0.001), >56% had minimally
important improvements in EQ-5D utility scores (PZ 0.012), and >65% were severe exacerba-
tion-free (P< 0.001). Significant reductions in healthcare utilization compared to the one year
prior to treatment were noted.
Conclusion: The PERSIST study shows better physician-rated effectiveness, greater improve-
ments in quality of life, greater reductions in exacerbation rates, and greater reductions in
healthcare utilization than previously reported in efficacy studies. Under real-life conditions,
omalizumab is effective as add-on therapy in the treatment of patients with persistent severe
allergic asthma.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Over the past four decades, the prevalence of and morbidity
and mortality associated with asthma has increased
substantially.1 As there is no cure for asthma, the goal of
treatment is aimed at controlling the clinical aspects of the
disease.2 Despite established guidelines for the evaluation,
classification and treatment of asthma, the majority of
patients are controlled sub-optimally, especially those with
severe asthma.3,4 Omalizumab is a recombinant monoclonal
antibody designed to treat immunoglobulin E (IgE)-mediated
disease by inhibiting the binding of IgE to high-affinity
receptors on pro-inflammatory cells. Omalizumab as add-on
to previously initiated inhaled corticosteroids (ICS) and long-
acting b2-agonist (LABA) treatment represents a new ther-
apeutic approach for severe persistent allergic asthma.
The safety, tolerability, pharmacokinetics and pharmaco-
dynamics of single and multiple doses of omalizumab have
been studied in more than 4600 patients. In phase III trials of
patients with allergic asthma, perennial allergic rhinitis, and
seasonal allergic rhinitis, omalizumab compared to placebo
has been shown to reduce the number of asthma exacerba-
tions,5 lower concomitant medication burden,6 improve
symptom severity, and enhance quality of life (QoL).7,8 In the
INNOVATE trial,5 now commonly used as an omalizumab effi-
cacy benchmark study, treatment efficacy was rated as good/
excellent in 60.5% of patients, and 60.8% had clinically
meaningful improvements in asthma-related QoL after 28
weeks of treatment.5 Moreover, omalizumab decreased clin-
ically significant exacerbation rates by 26%, and severe
exacerbation rates by 50%.5 Similar omalizumab treatment
effectiveness has been observed in recent open-label
studies.9,10
As with all asthma treatments,11 there is some hetero-
geneity in response to treatment with omalizumab. Oma-
lizumab treatment efficacy is often evaluated at 16 weeks,
with a response to treatment rate close to 61% as measured
by the global evaluation of treatment effectiveness
(GETE).5 In many patients, however, continued, long-term
treatments are essential to improve respiratory outcomes,reduce exacerbations and associated healthcare resource
utilization, and enhance QoL.7 Despite the efficacy
evidence from controlled trials and the emerging effec-
tiveness findings, the outcomes of omalizumab treatment
for persistent severe allergic asthma under real-life vari-
ability in patients, settings, and physicians remain poorly
documented. This was the purpose of the present study.Methods
Study design
PERSIST was a prospective, open-label, observational,
multicenter study in patients with severe persistent allergic
asthma treated with omalizumab. The primary objectives of
PERSIST were to: 1) describe the patients who, in their
treating physician’s best clinical judgment, were being
treated with omalizumab, 2) determine the 16- and 52-week
effectiveness of omalizumab as add-on therapy, 3) describe
treatment patterns involving add-on omalizumab treatment,
and 4) describe the safety and tolerability of treatment with
omalizumab when used in a pragmatic trial. As a secondary
objective, patients’ healthcare resource utilization patterns
over the 52-week treatment period were assessed and
compared to the one year prior to starting omalizumab.
All visits in PERSIST coincided with visits required by the
Belgian authorities for the reimbursement of omalizumab and
as such integrated into routine practice. During the baseline
patient assessment, data onhealthcare utilization visits in the
one year prior to starting omalizumab were collected histor-
ically. Approximately 16 weeks after the first treatment with
omalizumab, the treating physician determined whether to
continue omalizumab therapy in accordance with the scien-
tific leaflet and the Belgian reimbursement criteria. Treat-
ment was continued if the patient showed response to
treatment at 16 weeks; any such patient was followed for the
remainder of the study (approximately 52 weeks). Patients
who discontinued omalizumab therapy were asked to remain
in the study (Fig. 1).
Omalizumab in severe persistent allergic asthma 1635The PERSIST study included patients for whom the
treating physician decided, in his/her best clinical judg-
ment, to prescribe omalizumab, in accordance with the
scientific leaflet and the Belgian reimbursement criteria.
Physicians were approached for participation in PERSIST
based on their potential use of omalizumab in patients with
severe persistent allergic asthma seen in their practice.
Participating physicians enrolled all patients treated with
omalizumab in their practice who met inclusion criteria if
they provided written informed consent during the 24
month enrollment period from September 2006 to
September 2008. Study eligible patients were at least 12
years of age, had poorly controlled severe persistent
allergic asthma despite taking at least an ICS and a LABA
according to the 2005 global initiative for asthma (GINA)
guidelines, and had given written informed consent prior to
inclusion in the study. Patients were excluded from
participation if they were pregnant or nursing. As per
Belgian reimbursement criteria, eligible patients had
a baseline IgE 76 IU/mL, a positive radioallergosorbent
test, percentage of predicted forced expiratory volume in
1 sec (FEV1) <80%, regularly occurring day or nighttime
asthma symptoms, and at least two documented asthma
exacerbations requiring systemic corticosteroids, emer-
gency services, or hospitalization during the previous two
years. A total of 183 patients were screened for inclusion in
PERSIST; 160 patients were enrolled, and 158 met inclusionPre-S
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Figure 1 PERSIST study patient flow. ITTZ intent-tcriteria and had effectiveness data collected. Human
subjects approval for the study was granted by the Ethical
Committee of the University of Ghent. The Ethical
Committee of each center approved the study for local
participation.
Measurement of effectiveness
Prescribing physicians were asked to judge if there was an
improvement in 2005 GINA asthma classification (based on
asthma symptoms and lung function) at 16 and 52 weeks.
During the conduct of the study,GINA classificationof asthma
changed considerably.2 Thus, the frequency of daytime and
nocturnal asthma symptoms and FEV1 were also recorded.
Prescribing physicians were asked to rate the effec-
tiveness of omalizumab at 16 and 52 weeks using the global
evaluation of treatment effectiveness (GETE) scale. In the
GETE scale the treating physician judges whether the
patient’s overall response to treatment is excellent, good,
moderate, poor, or if the patient’s condition is worsening.
Subjective asthma-related QoL was assessed at baseline
and at 16 and 52 weeks, using the Juniper asthma-related
QoL questionnaire (AQLQ).12 A change of 0.5 on the 7-
point AQLQ scale represents a clinically meaningful
improvement in asthma-related QoL. In addition, generic
QoL was assessed using the European quality of life ques-
tionnaire 5 dimensions (EQ-5D) at baseline and 52 weeks.creening
= 183
 Enrolled
= 160
Not Enrolled (n = 23)
7 - did not provide consent
8 - reimbursement issue
2 - investigator withdrawal
6 - recruitment after open
enrollment
 Evaluable
= 158 Did not complete V2 (n = 5)
1 - death
1 - non-adherence
1 - other (not specified)
2 - stopped drug (not
specified) + no data
(≈52 weeks)
130 (ITT)
105 (PP)
Did not complete V3 (n = 12)
(9 on omalizumab)
1 - death
7 - lost to follow-up
1 - withdrew consent
3 - stopped participation
(≈16 weeks)
153 (ITT)
146 (PP)
No effectiveness data (n = 2)
o-treat population, PPZ per-protocol population.
Table 1 Baseline characteristics of patients treated with
omalizumab.
Baseline characteristics nZ 158
Age (years)
Mean (SD) 48.17 (17.18)
Median (range) 49.50 (12e83)
Gender n (%)
Male 73 (46.2%)
Female 85 (53.8%)
Race n (%)
Caucasian 150 (94.9%)
Other 8 (5.1%)
Weight (kg)
Mean (SD) 71.46 (16.53)
Median (range) 72.00 (32e118)
Smoking history
Current smoker 16 (10.1%)
Former smoker 33 (20.9%)
Never smoked 109 (69%)
FEV1 (% of predicted)
Mean (SD) 56.54 (14.72)
Median (range) 57.50 (22e92)
IgE (IU/mL)
Mean (SD) 613.89 (860.19)
Median (range) 317.00 (40e5152)
AQLQ total
score (nZ 157)
Mean (SD) 3.24 (1.21)
Median (range) 3.00 (1e6.3)
EQ-5D VAS (nZ 124)
Mean (SD) 52.29 (17.34)
Median (range) 53.50 (8e90)
EQ-5D index/utility (nZ 126)
Mean (SD) 0.54 (0.24)
Median (range) 0.58 (0.16e1.00)
Abbreviations: AQLQZ Juniper asthma-related quality of
life, EQ-5DZ European quality of life questionnaire 5 dimen-
sions, FEV1Z forced expiratory volume at 1 s (% predicted),
IgEZ immunoglobulin E, IUZ international units, kgZ kilo-
grams, SDZ standard deviation, VASZ visual analogue scale.
1636 G. Brusselle et al.According to established guidelines, EQ-5D utility data were
calculated using Belgian population norms.13 Taken from
established utilities from a broad range of chronic condi-
tions, a minimally important improvement in EQ-5D was
defined as an absolute increase of 0.074.14 Both the AQLQ
and EQ-5D are widely used in clinical research.
PERSIST severe exacerbations were those that met the
following criteria: the patient required a systemic cortico-
steroid, or the patient required an emergency room visit or
hospitalization for the exacerbation. The incidences of
PERSIST severe exacerbations were assessed at 16 and 52
weeks.
Note that prescribers are required to report GINA clas-
sification, GETE rating, and AQLQ total and subscores to
qualify patients for omalizumab reimbursement in Belgium.
Hence these data are recorded in routine clinical practice
and do not constitute additional burden on either patient or
physician.
Statistical methods
Data were analyzed using SPSS v15.0 (Chicago, Illinois,
USA), and Stata MP v10.0 (College Station, Texas, USA). The
level of statistical significance was set at 0.05. Data are
presented for both the intent-to-treat (ITT) e all patients
with visit data available e and the per-protocol (PP) e all
patients remaining on omalizumab e populations. Data
were summarized with respect to background and demo-
graphic characteristics, effectiveness measurements, as
well as safety observations using descriptive statistics of
frequency, central tendency, and dispersion under consid-
eration of applicable levels of measurement. As appro-
priate, paired t-tests or Wilcoxon Signed Ranks tests were
used to describe observed trends.
For measures of omalizumab treatment effectiveness,
the binomial test was used to test the null hypothesis that
the proportion of patients responding to treatment with
omalizumab at 16 weeks was 0.605. This referent propor-
tion was derived from the INNOVATE study.5 The proportion
of patients with a) improvement in 2005 GINA classification,
b) GETE rating of good/excellent, c) improvement in AQLQ
total or subscales of 0.5 points, and d) the proportion
that was exacerbations-free at 16 weeks were tested.
The binomial test was also used to test the null hypothesis
that the proportion of patients responding to treatment
with omalizumab at 52 weeks was 0.605 adjusted for
a persistence failure of 0.30, therefore a proportion of
0.424. The proportion of patients with a) improvement in
2005 GINA classification, b) GETE rating of good/excellent,
c) improvement in AQLQ total or subscales of 0.5 points,
d) improvement in EQ-5D utility score of 0.074, and e) the
proportion that was exacerbation-free were tested.
Currently, the commonly accepted clinical criteria for
omalizumab treatment response is the GETE; patients with
a GETE of good or excellent are considered responders.15
Results
The baseline evaluable sample consisted of 158 patients
with severe persistent asthma enrolled from 35 partici-
pating centers. Patients ranged in age from 12 to 83 years(Table 1). Almost 54% were female and 94.9% of patients
were Caucasian. Mean IgE at baseline was high and ranged
widely (median 317, inter-quartile rangeZ 142.5e
661.0 IU/mL). Baseline generic and asthma-related QoL
were both in the low range (mean AQLQ total score: 3.24;
mean EQ-5D VAS: 52.29; mean EQ-5D utility score: 0.54). All
patients had poorly controlled asthma despite treatment
with high-dose ICS and a LABA (Table 2). In addition, 63.3%
were on oral corticosteroids. The majority of patients
(70.9%) experienced daily asthma symptoms, and a slight
majority (57%) experienced nocturnal symptoms weekly.
During the 12 months preceding enrollment 69 patients
had asthma-related general practitioner visits (mean[SD]
5.13[4.77], annual rate 2.44), 149 had specialist visits
(4.38[2.98] visits, annual rate 4.18), 22 had emergency
room visits (1.35[0.89] visits, annual rate 0.22), and 64
required hospitalization (1.44[0.89] hospitalizations,
annual rate 0.60). In the preceding 12 months, patients had
on average 2.67[1.28] PERSIST severe exacerbations.
Table 2 Indices of poor asthma control prior to
omalizumab.
Indices of poor
asthma control
n (%)
Concomitant medications
ICS plus LABA 158 (100)
Oral corticosteroid use
Intermittent 55 (34.8)
Daily 45 (28.5)
Leucotriene antagonists 102 (64.6)
Anticholinergics 63 (39.9)
Theophylline/derivatives 61 (38.6)
Antihistamines 45 (28.5)
Daytime symptoms
<Once/week 5 (3.2)
>Once/week 41 (25.9)
Daily 112 (70.9)
Nighttime symptoms
<2 Times/month 35 (22.2)
>2 Times/month 33 (20.9)
Weekly 90 (57.0)
Asthma-related healthcare
visits in past year
1 General
practitioner visit
69 (43.7)
1 Specialist visit 149 (94.3)
1 Emergency
room visit
22 (13.9)
1 Hospitalization 64 (40.5)
Asthma exacerbations
in past year
1 PERSIST severe exacerbation 155 (98.1)
Abbreviations: ICSZ inhaled corticosteroid, LABAZ long-
acting beta agonist.
Table 3 16-Week omalizumab treatment effectiveness
(Visit 2).
Population n 16-Week effectiveness P value
% Improving in 2005
GINA classification
ITT 153 37.9% <0.001
PP 146 38.4% <0.001
% With
good or excellent
GETE rating
ITT 153 82.4% <0.001
PP 146 83.8% <0.001
% Improving
in AQLQ total
score 0.5
ITT 147 82.3% <0.001
PP 142 83.8% <0.001
% PERSIST severe
exacerbation-free
ITT 132 90.9% <0.001
PP 125 91.2% <0.001
Tested against the null of 60.5% effectiveness.
Abbreviations: AQLQZ Juniper asthma-related quality of life,
GETEZ physician-rated global evaluation of treatment
effectiveness, GINAZ 2005 Global Initiative for Asthma,
ITTZ intent-to-treat population, PPZ per-protocol population.
Omalizumab in severe persistent allergic asthma 163716-Week treatment effectiveness
At 16 weeks, the ITT sample included 153 and the PP sample
146 patients. Using the 0.605 INNOVATE responder propor-
tion, this sample size permitted detection of such propor-
tion and associated 95% confidence interval (CI) with
precision of 0.077.
16-Week 2005 GINA classification, asthma
symptoms and lung function
Over a mean[SD] study duration of 15.92[9.77] weeks,
37.9% of the ITT population (P< 0.001), and 38.4% of the PP
population (P< 0.001) were judged to have an improve-
ment in 2005 GINA classification (Table 3). Reduction in the
frequency of daytime symptoms was observed in 60.8% of
the ITT population (PZ non-significant (ns)), and 62.3% of
the PP population (PZ ns). Reduction in the frequency of
nocturnal symptoms was observed in 52.9% of the ITT
population (PZ 0.034) and 54.1% of the PP population
(PZ ns). FEV1 data were available on 87.5% (nZ 134) of
the ITT population and 89% (nZ 130) of the PP population.
FEV1 improved significantly from baseline in both the ITT
(mean[SD] improvement 12.20[19.41]%) and PP populations
(11.70[18.00]%) (both P< 0.001).16-Week physician-rated GETE
82.4% of the ITT and 83.6% of the PP population had good/
excellent GETE ratings (both P< 0.001).
16-Week quality of life
82.3% of the ITT population had an improvement of total AQLQ
scores of 0.5 points (P< 0.001). There was a moderate
improvement in total AQLQ (1.0 points)9 in 67.8% of the ITT
population, and a large improvement in AQLQ (1.5 points)9 in
36.7% of the ITT population. The mean[SD] 16-week
improvement in total AQLQ score was 1.37[1.09] for the ITT
population. 83.8% of the PP population had an improvement in
total AQLQ scores of at least 0.5 points (P< 0.001). Similar
results were observed for all four AQLQ subscales.
Exacerbations at 16 weeks
During the first 16 weeks of treatment with omalizumab, 12
patients (9.1%) in the ITT population had at least one PERSIST
severe exacerbation (range 1e2). 90.9% of the ITT population
were PERSIST severe exacerbation-free (P< 0.001). In the PP
population, 11 patients (8.8%) had at least one PERSIST severe
exacerbation. 91.2% of the PP population were PERSIST severe
exacerbation-free (P< 0.001) after 16 weeks of treatment.
52-Week treatment effectiveness
At 52 weeks, the ITT sample included 130 patients and the
PP sample 105 patients. Using the 0.605 INNOVATE
1638 G. Brusselle et al.responder proportion adjusted for persistent failure
(0.424), this sample size permitted detection of such
proportion and associated 95% CI with precision of 0.107.
52-Week 2005 GINA classification, symptoms and
lung function
Over a mean[SD] study duration of 56.43[11.03] weeks, 31%
of the ITT population was judged to have an improvement in
2005 GINA classification (PZ 0.005), as was 35.2% of the PP
population (PZ ns) (Table 4). Compared to baseline,
daytime symptoms were reduced in 63.8% of the ITT pop-
ulation (P< 0.001), and in 72.4% of the PP population
(P< 0.001). Nocturnal symptoms were reduced in 49.2% of
the ITTpopulation (PZ ns), and in 54.3%of thePPpopulation
(PZ 0.009). FEV1 improved significantly compared to base-
line in both the ITT (mean[SD] improvement 12.23[24.18]%)
and PP populations (12.72[25.39]%) (both P< 0.001).
52-Week physician-rated GETE
After 52 weeks of participation, 72.3% of the ITT population
had a good/excellent GETE rating (P< 0.001). 80.9% of the PPTable 4 52-Week omalizumab treatment effectiveness
(Visit 3).
Population n 52-Week effectiveness P value
% Improving in 2005 GINA
classification
ITT 130 31.0% <0.005
PP 105 35.2% <0.082
% With
good or excellent GETE rating
ITT 130 72.3% <0.001
PP 105 80.9% <0.001
% Improving
in AQLQ Total
Score 0.5
ITT 122 84.4% <0.001
PP 100 89.0% <0.001
% Improving
in EQ-5D utility
score 0.074 points
ITT 67 56.7% 0.012
PP 54 57.6% 0.019
% PERSIST severe exacerbation-
free
ITT 128 65.6% <0.001
PP 103 66.0% <0.001
Tested against the null of 42.4% effectiveness. All results shown
reflect full 52-week duration of the study.
Abbreviations: AQLQZ Juniper asthma-related quality of life
questionnaire, GETEZ physician-rated global evaluation of
treatment effectiveness, GINAZ 2005 Global Initiative for
Asthma, EQ-5DZ European quality of life questionnaire 5 dimen-
sions, ITTZ intent-to-treat population, PPZ per-protocol
population.population had a good/excellent GETE rating (P< 0.001)
(Fig. 2).
52-Week quality of life
Comparative AQLQ data were available on 122 (93.8%) of
the ITT population. 84.4% of the ITT population had an
improvement in total AQLQ score of 0.5 points
(P< 0.001), 68.9% had an improvement of 1point, and
53.3% had an increase in total AQLQ score of 1.5points
compared to baseline. The mean[SD] 52-week improvement
in total AQLQ score was 1.79[1.13] for the ITT population
(Fig. 3). Comparative AQLQ data were available on 100
(95.2%) of the PP population. 89% of the PP population had
improvement in total AQLQ score of 0.5 points compared
to baseline (P< 0.001). At 52 weeks, 76% of the PP pop-
ulation had an improvement in total AQLQ score of
1.0point and 59% had an increase in total AQLQ score of
1.5points compared to baseline. Similar results were
observed with all four AQLQ subscales.
Comparative EQ-5D datawere available on 51.5% (nZ 67)
of the ITT population, and 51.4% (nZ 54) of the PP pop-
ulation. General health, as estimated by the EQ-5D visual
analogue scale, increased significantly in the ITT (mean[SD]
difference 14.22[20.99]), and PP populations (15.82[20.41])
(both P< 0.001) (Fig. 4). EQ-5D utility scores also increased
significantly in the ITT (mean[SD] improvement 0.14[0.23]),
and PP populations (0.15[0.24]) (both P< 0.001). In addi-
tion, 56.7% of the ITT population (PZ 0.012) and 57.6% of
the PP population (PZ 0.019) had minimally important
improvements in EQ-5D utility (0.074).
Exacerbations at 52 weeks
During the 12 month duration of the study, 44 (34.4%) in the
ITT population had at least one PERSIST severe exacerba-
tion. In the ITT population, 65.6% were PERSIST severe
exacerbation-free during the 12 month duration of the
study (P< 0.001). During the duration of the study, 34 (33%)
of the PP population had at least one PERSIST severe
exacerbation. 66.0% of the PP population was PERSIST
severe exacerbation-free during the 12 month duration of
the study (P< 0.001). Compared to the one year prior to
omalizumab treatment, exacerbation rates were substan-
tially reduced during treatment (Fig. 5).
Treatment patterns
62% of patients were started on omalizumab injections every
2 weeks (Q2W), while the remainder (38%) started on a Q4W
regimen. The mean[SD] Q2W dose was 314.54[63.4] mg,
while the average Q4W dose was 247.5[73.46] mg. The total
average starting monthly dose was 484.18[215.58] mg. The
modal regimen (29.1%) was 375 mg Q2W.
Deviations from recommended treatment
Potential under-prescribing occurred in 36 participants
(22.8%); 30 study participants (18.9%) were started on
omalizumab despite having a weight and/or IgE levels
above the recommended range, and 6 study participants
Figure 2 Omalizumab treatment effectiveness in the PERSIST study. Proportion of PERSIST populations with evidence of
treatment effectiveness. % improvement in total AQLQ indicates an improvement in total AQLQ score 0.5 points, % PERSIST severe
exacerbation-free indicates no evidence of a PERSIST severe exacerbation. ITT 16-week nZ 153, 52-week nZ 130. PP 16-week
nZ 146, 52-week nZ 105. Abbreviations: AQLQZ asthma quality of life questionnaire, GETEZ physician-rated Global Evaluation
of Treatment Effectiveness, ITTZ intent-to-treat population, PPZ per-protocol population.
Omalizumab in severe persistent allergic asthma 1639(3.8%) were started on a lower dose than recommended
(including one who also was started at a lower frequency
than recommended). The most common reasons for starting
these patients on omalizumab were severity of disease or
the prescribing physician’s perceived therapeutic benefit.
Potential over-prescribing occurred in four participants
(2.5%); two had IgE levels lower than the reimbursement
criterion (<76 IU/mL), one was started on a higher dose and
one was started at a higher frequency than recommended.
After 16 weeks of treatment, one patient was changed to
300 mg Q3W, and one to 450 mg Q2W. Both of these regi-
mens differed from prescribing guidelines. Additionally, at
16 weeks, 27 patients (20.8%) were continued on baseline
omalizumab dosing, despite baseline IgE and/or a 16-week
weight above the dosing range. There was no significant
difference in the change in GINA classification, GETE rating,
indices of QoL, or frequency of exacerbations or healthcareFigure 3 Improvement in asthma-related quality of life during
omalizumab treatment: Mean absolute change in AQLQ scores
during treatment with omalizumab relative to baseline for the
intent-to-treat population. Clinically meaningful improvement in
AQLQ score (0.5 points) marked by dashed line. 16-week
nZ 147, 52-weeknZ 122.AllP values<0.01 relative tobaseline.
Abbreviations: AQLQZ asthma quality of life questionnaire.visits comparing patients with IgE levels 700 IU/mL and
those with IgE levels >700 IU/mL at 16-weeks or 52-weeks
of treatment (all P values >0.05) (data not shown).
Concomitant medication reduction
Over 52 weeks, 24 patients (18.45%) had methylpredniso-
lone discontinued altogether and there was a 39.4%
reduction in the average daily dose of methylprednisolone
(7.31[13.86] mg, P< 0.001). There was a 10.1% reduction in
the average daily dose of budesonide (mean[SD] reduction
94.14[352.48] mcg, PZ 0.047), a 9.6% reduction in the
average daily dose of formoterol (3.03[11.16] mg,
PZ 0.038). Additionally, leucotriene antagonists were dis-
continued in 9 (Wilcoxon signed ranks PZ ns), anticholin-
ergics in 11 (PZ 0.013), antihistamines in 6 (PZ ns), and
theophylline/derivatives in 5 patients (PZ ns).Safety and tolerability
Overall, 55.6% (nZ 89) of patients treated with omalizu-
mab experienced at least one adverse event (AE). The
majority of AEs reported were consistent with the omali-
zumab scientific leaflet. That is, nearly half of all AEs (46%)
were respiratory disorders, especially asthma exacerba-
tions and respiratory infections compatible with the course
of the underlying disease or concurrent infections. Indi-
vidual AEs with a frequency 5% included cutaneous or
subcutaneous disorders (not local), vascular disorders,
headache, cough, immune disorders (facial edema, tight
throat), tiredness, and gastrointestinal disorders. 39
patients (24.4%) experienced severe AEs mainly related to
asthma exacerbations or other respiratory complications;
12 patients (7.5%) had severe AEs suspected to be related to
omalizumab. There were 19 (12.0%) omalizumab discon-
tinuations due to AEs (Table 5). Four patients died during
the study periods; none of those deaths was attributed to
omalizumab. One of them was discussed previously.16
Figure 4 Improvements in EQ-5D utilities and general health during treatment with omalizumab. Changes in Belgian (Flemish)
population norm-weighted EQ-5D utilities and general health (as measured by the VAS) for the intent-to-treat population (nZ 67).
Average change represented as mean (95% confidence interval). P value indicates significance of paired t-test. Abbreviations: EQ-
5DZ European quality of life questionnaire, VASZ visual analogue scale.
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Overall, incidences of asthma-related healthcare utilization
decreased during the 52 weeks of the study compared to the
preceding year. 74 of 126 study participants (58.7%) had
fewer healthcare visits (defined as general practitioner
visits; specialist visits; emergency room visits; and hospital-
izations) during the study than theprevious year.Over the52-
week treatment with omalizumab, there was a mean[SD]
reduction of 1.49[7.56] healthcare visits (PZ 0.028). There
was a reduction in total healthcare utilization of 18.68% in
the ITT population, and of 22.9% in the PP population. 47
studyparticipants had seen general practitioners prior to and
during the study. Over the course of the 52-week treatment
with omalizumab, there was a mean[SD] reduction of
3.72[6.09] GP visits (P< 0.001). 117 participants had seen
specialists prior to and during the study. There was a non-
significant trend favoring amean[SD] increase of 0.829[4.80]
specialist visits (PZ 0.064). Included in this analysis are allFigure 5 Comparison of annual severe exacerbation rates on
omalizumab: Annual PERSIST severe exacerbation rates during
the 52 weeks of treatment with omalizumab compared to
annual severe exacerbation rates during the 52 weeks preceding
treatment. ITT nZ 130; PP nZ 105. Abbreviations: ITTZ in-
tent-to-treat population, PPZ per-protocol population.visits including appointments for omalizumab injections;
thus, the increase in specialist visits can be explained, at
least in part, by the way omalizumab is prepared and
administered. There were decreasing trends observed in
both emergency visits and hospitalizations, but neither
reached statistical significance.
Discussion
During the PERSIST study, we observed the therapeutic
effectiveness of omalizumab prescribed as add-on therapy
to treat severe persistent allergic asthma in routine
medical practice in Belgium. During this study, physician-
rated effectiveness was good or excellent in the vast
majority of patients studied. In addition, we observed
significant improvements in QoL and lung function, as well
as significant reductions in severe asthma exacerbations
and the frequency of daytime and nighttime symptoms.
Moreover, there were reductions in incidence and rates of
healthcare utilization in the majority of patients studied.
In most instances, the proportion of participants
responding to treatment with omalizumab was greater than
anticipated in reference to the results of large efficacy5,6,8
and open-label studies.9,10 Specifically, the PERSIST study
shows better physician-rated effectiveness,5,8 greater
improvements in QoL,5,9,15 and more pronounced reduc-
tions in exacerbation rates than previously repor-
ted.5,10,15,17 Further, reductions in healthcare utilization
were superior than previously reported.5,10,17 These
differences in effectiveness may be due, at least in part, to
the fact that participants selected for treatment withTable 5 PERSIST major reasons for discontinuation.
Death 4 (2.5%)
All adverse event(s) 19 (12.0%)
Lack of effectiveness 21 (13.3%)
Administrative reasons 5 (3.2%)
Lost to follow-up 7 (4.4%)
Other (including non-
adherence)
16 (10.1%)
Note: There were multiple reasons for discontinuation in some
cases.
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this study presented with a greater asthma severity
compared with the samples of other efficacy and other
observational studies. For example, in comparison to
INNOVATE5 and in part to an analysis of a merged sample of
2511 patients,17 subjects in PERSIST were older, had worse
baseline pulmonary function, higher levels of IgE, and more
were taking maintenance oral corticosteroids. Moreover,
compared to the sample of a recent effectiveness study,9
participants in PERSIST were 10 years older on average, had
a longer asthma duration and therefore had worse baseline
pulmonary function. In general, our sample characteristics
indicate a patient segment with more severe pathology
compared to the samples of other studies of omalizumab
perhaps leading to the possibility of greater improvements
observed in this study.
The patients in PERSIST had a worse QoL at baseline
compared to those in INNOVATE.5 In fact, baseline QoL (as
assessed by both the AQLQ and EQ-5D) was comparable to
that during an exacerbation requiring oral corticosteroids in
a study of asthma patients from the United Kingdom.18
Perhaps the higher than expected effectiveness of omalizu-
mab in this study reflects a sample of patients who had more
therapeutic benefit to gain than those in prior efficacy and
effectiveness studies. Higher levels of medication compli-
ance with omalizumab injections (administered by medical
providers) compared to other patient-administered asthma
medication also may have been a factor in overall thera-
peutic effectiveness.
For most of the treating physicians, this study was their
first experience with omalizumab outside of the confines of
a clinical trial. Thus, participating physicians may have
selected patients with more to gain from a new and
effective severe asthma treatment. When omalizumab has
been available for a longer period of time, the composition
of participant characteristics will be interesting to trend.
There were also several variations observed in omalizumab
dosing, including several instances of IgE levels above and
below the dosing guidelines, and failure to adjust per
patient weight. But, these deviations in prescribing
patterns likely reflect use of omalizumab in a naturalistic
setting. Overall, the results reported herein suggest that
omalizumab is effective in improving lung function and
frequency of asthma symptoms, improving QoL, reducing
exacerbations, reducing use of oral corticosteroids and
reducing healthcare utilization under the conditions of
real-life clinical practice and real-patient heterogeneity.Study limitations and implications thereof
PERSIST was an observational, open-label, pharmaco-
epidemiologic study, not a randomized, controlled trial.
Although in general, observational studies do not over-
estimate treatment effects,19,20 our study has limitations
and revealed areas where more clarity is needed. For
example, future research is needed to validate, if not
extend, our findings regarding physician-rated effective-
ness, as well as improvements in QoL, exacerbation rates
and healthcare utilization that were greater in this
heterogeneous population than reported in recent studies
of omalizumab. However, it is likely that the reduction inhealthcare utilization following omalizumab use has been
underestimated due to the retrospective (as opposed to
prospective) healthcare resources data collection for the
one year period preceding omalizumab use. This study was
conducted in one European country; thus, multi-national
and multi-cultural follow-on studies are necessary. Further,
this study, though adequately powered, was not a pop-
ulation-based study. Thus, despite efforts to ensure pop-
ulation representativeness, patient selection based on
physician perceived benefit may have been a factor.
Conclusion
Patients selected to be treated with omalizumab by physi-
cians under ‘‘real-life’’ treating conditions in Belgium had
a longer asthma duration and presented with a greater
asthma severity in comparison to patients of other trials/
studies. Significant improvements were observed in pulmo-
nary function and the frequency of daytime and nocturnal
symptom, physician-rated global effectiveness,QoL and rate
of asthma exacerbation. Overall, the study results provide
evidence that omalizumab is effective as add-on therapy in
the management of severe persistent allergic asthma.
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